Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy

Biomaterials - Tập 34 - Trang 3447-3458 - 2013
Yuan Zhang1, William Y. Kim2, Leaf Huang1
1Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 1315 Kerr Hall CB# 7571, Chapel Hill, NC 27599-7571, USA
2Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

Tài liệu tham khảo

Achanta, 2001, Interaction of p53 and DNA- PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage, Cancer Res, 61, 8723 Parker, 2009, Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer, Chem Rev, 109, 2880, 10.1021/cr900028p Senanayake, 2011, Novel anticancer polymeric conjugates of activated nucleoside analogues, Bioconjug Chem, 22, 1983, 10.1021/bc200173e van Moorsel, 1997, Gemcitabine: future prospects of single-agent and combination studies, Oncologist, 2, 127, 10.1634/theoncologist.2-3-127 Hung, 2012, Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge, Cancer Lett, 320, 138, 10.1016/j.canlet.2012.03.007 Allain, 2012, Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices, Nucleic Acids Res, 40, 1891, 10.1093/nar/gkr681 Rejiba, 2011, Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer, Nanomedicine, 7, 841, 10.1016/j.nano.2011.02.012 Li, 2010, Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery, J Control Release, 142, 416, 10.1016/j.jconrel.2009.11.008 Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res, 46, 6387 Li, 2009, Nanoparticles evading the reticuloendothelial system: role of the supported bilayer, Biochim Biophys Acta, 1788, 2259, 10.1016/j.bbamem.2009.06.022 Banerjee, 2004, Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells, Int J Cancer, 112, 693, 10.1002/ijc.20452 Li, 2012, Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor, J Control Release, 158, 108, 10.1016/j.jconrel.2011.10.020 Zhang, 2011, Octreotide-modified polymeric micelles as potential carriers for targeted docetaxel delivery to somatostatin receptor overexpressing tumor cells, Pharm Res, 28, 1167, 10.1007/s11095-011-0381-1 Risbood, 2008, Synthesis of gemcitabine triphosphate (dFdCTP) as a tris(triethylammonium) salt, Bioorg Med Chem Lett, 18, 2957, 10.1016/j.bmcl.2008.03.063 Karl, 1980, Effects of alkaline phosphatase activity on nucleotide measurements in aquatic microbial communities, Appl Environ Microbiol, 40, 549, 10.1128/AEM.40.3.549-561.1980 Kim, 2009, Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice, J Control Release, 140, 55, 10.1016/j.jconrel.2009.07.005 Johnson, 2000, Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies, Clin Pharmacokinet, 39, 5, 10.2165/00003088-200039010-00002 Cohen, 1997, Caspases: the executioners of apoptosis, Biochem J, 326, 1, 10.1042/bj3260001 Arya, 2011, Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy, Nanomedicine, 7, 859, 10.1016/j.nano.2011.03.009 Tang, 2012, EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer, PLoS One, 7, e31067, 10.1371/journal.pone.0031067 Andreeva, 2001, Evaluation of cell proliferation in human atherosclerotic lesions, Methods Mol Med, 52, 213 Hornick, 2012, Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands, Surgery, 152, S152, 10.1016/j.surg.2012.05.014 Riganas, 2012, Synthesis, sigma(1), sigma(2)-receptors binding affinity and antiproliferative action of new C1-substituted adamantanes, Bioorg Med Chem, 20, 3323, 10.1016/j.bmc.2012.03.038 Everaert, 1997, Sigma-receptor imaging by means of I123-IDAB scintigraphy: clinical application in melanoma and non-small cell lung cancer, Anticancer Res, 17, 1577 White, 1987, Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells, J Clin Invest, 79, 380, 10.1172/JCI112823 Brusa, 2007, Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs, Anticancer Res, 27, 195 Immordino, 2004, Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs, J Control Release, 100, 331, 10.1016/j.jconrel.2004.09.001 Lansakara, 2012, Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles, Int J Pharm, 429, 123, 10.1016/j.ijpharm.2012.03.014 Sarpietro, 2011, Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers, Int J Pharm, 406, 69, 10.1016/j.ijpharm.2010.12.038 Li, 2010, Synthesis of lamivudine stearate and antiviral activity of stearic acid-g-chitosan oligosaccharide polymeric micelles delivery system, Eur J Pharm Sci, 41, 498, 10.1016/j.ejps.2010.08.004 Meier, 2006, Application of the cycloSal-prodrug approach for improving the biological potential of phosphorylated biomolecules, Antiviral Res, 71, 282, 10.1016/j.antiviral.2006.04.011 Zhang, 2012, In vivo gene delivery by nonviral vectors: overcoming hurdles?, Mol Ther, 20, 1298, 10.1038/mt.2012.79 Xu, 1996, Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection, Biochemistry, 35, 5616, 10.1021/bi9602019